H Allain

Summary

Country: France

Publications

  1. ncbi request reprint Five-year follow-up of early lisuride and levodopa combination therapy versus levodopa monotherapy in de novo Parkinson's disease. The French Lisuride Study Group
    H Allain
    Laboratoire de Pharmacologie Expérimentale et Clinique et Service de Neurologie, Faculte de Medecine, Universite de Rennes I, Rennes
    Eur Neurol 44:22-30. 2000
  2. ncbi request reprint Aminotransferase levels and silymarin in de novo tacrine-treated patients with Alzheimer's disease
    H Allain
    Laboratoire de Pharmacologie Experimentale et Clinique, Faculte de Medecine, Universite de Rennes I, Rennes, France
    Dement Geriatr Cogn Disord 10:181-5. 1999
  3. ncbi request reprint Progress in understanding the pathophysiology of cerebral ischemia: the almitrine-raubasine approach
    D Bentue-Ferrer
    Laboratoire de Pharmacologie Experimentale et Clinique, Faculte de Medecine, Rennes, France
    Clin Neuropharmacol 13:S9-25. 1990
  4. ncbi request reprint [Parkinson disease: interrogations and solutions]
    H Allain
    Laboratoire de Pharmacologie Experimentale et Clinique, Faculte de Medecine, Rennes
    Presse Med 26:909-15. 1997
  5. ncbi request reprint Clinical efficacy of almitrine-raubasine. An overview
    H Allain
    Laboratoire de Pharmacologie Experimentale et Clinique, Faculte de Medecine, Rennes, France
    Eur Neurol 39:39-44. 1998
  6. ncbi request reprint [Psychiatry and clinical research. A dialogue with hospital directors]
    H Allain
    Laboratoire de Pharmacologie, Faculte de Medecine, Universite de Rennes I
    Presse Med 29:1768-72. 2000
  7. ncbi request reprint Comparative effects of pharmacotherapy on the maintenance of cognitive function
    H Allain
    Department of Pharmacology, Faculte de Medecine, Universite de Rennes I, 2, avenue du professeur Leon Bernard, 35043 Rennes Cedex, France
    Eur Psychiatry 16:35s-41s. 2001
  8. ncbi request reprint [Perspectives for drug treatment in Alzheimer's disease]
    H Allain
    Laboratoire de Pharmacologie, Faculte de Medecine, Universite de Rennes I, 2, avenue du Pr Leon Bernard, CS 34317, 35043 Rennes Cedex, France
    Ann Med Interne (Paris) 152:527-32. 2001

Collaborators

  • N Mauduit
  • D Bentue-Ferrer
  • R Decombe
  • C Schatz
  • J M Reymann

Detail Information

Publications8

  1. ncbi request reprint Five-year follow-up of early lisuride and levodopa combination therapy versus levodopa monotherapy in de novo Parkinson's disease. The French Lisuride Study Group
    H Allain
    Laboratoire de Pharmacologie Expérimentale et Clinique et Service de Neurologie, Faculte de Medecine, Universite de Rennes I, Rennes
    Eur Neurol 44:22-30. 2000
    ..7 vs. 387.5 mg/day). Long-term follow-up demonstrated the L-dopa-sparing effect of lisuride (average 1 mg/day), the beneficial effect of early combination therapy on motor status and the paucity of motor complications in both groups...
  2. ncbi request reprint Aminotransferase levels and silymarin in de novo tacrine-treated patients with Alzheimer's disease
    H Allain
    Laboratoire de Pharmacologie Experimentale et Clinique, Faculte de Medecine, Universite de Rennes I, Rennes, France
    Dement Geriatr Cogn Disord 10:181-5. 1999
    ....
  3. ncbi request reprint Progress in understanding the pathophysiology of cerebral ischemia: the almitrine-raubasine approach
    D Bentue-Ferrer
    Laboratoire de Pharmacologie Experimentale et Clinique, Faculte de Medecine, Rennes, France
    Clin Neuropharmacol 13:S9-25. 1990
    ....
  4. ncbi request reprint [Parkinson disease: interrogations and solutions]
    H Allain
    Laboratoire de Pharmacologie Experimentale et Clinique, Faculte de Medecine, Rennes
    Presse Med 26:909-15. 1997
    ..Since the inaugural description in 1817 by J. Parkinson, therapeutic progress rapidly accelerated mainly due to a better knowledge of the neurobiology of the central nervous system dopaminergic pathways...
  5. ncbi request reprint Clinical efficacy of almitrine-raubasine. An overview
    H Allain
    Laboratoire de Pharmacologie Experimentale et Clinique, Faculte de Medecine, Rennes, France
    Eur Neurol 39:39-44. 1998
    ..The appropriate and usual dosage (2 tablets per day) and the good tolerance of the compound have been confirmed in a French multicentric study in 5,361 outpatients...
  6. ncbi request reprint [Psychiatry and clinical research. A dialogue with hospital directors]
    H Allain
    Laboratoire de Pharmacologie, Faculte de Medecine, Universite de Rennes I
    Presse Med 29:1768-72. 2000
    ..Incentive politics as well as avoidance of technical and frequently definitive errors must be proned and issue from a deep analysis of how leading teams are organized and operate...
  7. ncbi request reprint Comparative effects of pharmacotherapy on the maintenance of cognitive function
    H Allain
    Department of Pharmacology, Faculte de Medecine, Universite de Rennes I, 2, avenue du professeur Leon Bernard, 35043 Rennes Cedex, France
    Eur Psychiatry 16:35s-41s. 2001
    ..As an illustration of this approach we shall relate two studies, TIATEM (phase I) and TIAGE (phase III/IV), leading to the determination of a good cognitive safety profile of an atypical neuroleptic drug, tiapride...
  8. ncbi request reprint [Perspectives for drug treatment in Alzheimer's disease]
    H Allain
    Laboratoire de Pharmacologie, Faculte de Medecine, Universite de Rennes I, 2, avenue du Pr Leon Bernard, CS 34317, 35043 Rennes Cedex, France
    Ann Med Interne (Paris) 152:527-32. 2001
    ..The main goal of the present review is to summarize the state-of-the-art for a non specialist in AD...